# US 2006/0154976 A1 · Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154976 A1
- Document ID: US20060154976A1
- Status: Published application
- Kind: A1
- Application number: 11/375,836
- Filed: 2006-03-15
- Published: 2006-07-13
- Earliest claimed: 2000-08-22
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Peter Boehm; Wolf Meinicke; Axel Riedel
- Web page: https://patentgrep.com/patent/US20060154976A1

## CPC

- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/415: 1,2-Diazoles
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/556: {Angiotensin converting enzyme inhibitors}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 11/16: Central respiratory analeptics
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

## Claims

### Claim 1

A method of treating, reducing the incidence of fibrosis, said method comprising the co-administration to a patient in need thereof, an effective amount of an angiotensin II antagonist telmisartan and an effective amount of an ACE inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ACE inhibitor is benazepril, captopril, ceronapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, quinapril, ramipril, trandolapril, or perindopril.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ACE inhibitor is ramipril.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ACE inhibitor is administered in a daily dosage of 0.018 mg/kg to 0.571 mg/kg orally or of about 0.286 mg/kg parenterally and the angiotensin II antagonist telmisartan is administered in a daily dosage of 0.143 mg/kg to 7.143 mg/kg orally or of about 0.286 mg/kg parenterally.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the patient treated has elevated blood pressure or congestive heart failure.

### Claim 6

A pharmaceutical composition comprising the ACE inhibitor, ramipril and the angiotensin II antagonist, telmisartan.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6, wherein rampiril is used in an amount of about 1.25 mg to about 100 mg and telmisartan in amount of about 20 mg to about 100 mg in single dosage units.
